Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer
文献类型：期刊论文
| 作者 | Xie, Cheng-Ying ; Xu, Yong-Ping; Jin, Wei; Lou, Li-Guang
|
| 刊名 | ANTI-CANCER DRUGS
 |
| 出版日期 | 2012-08 |
| 卷号 | 23期号:7页码:698-705 |
| 关键词 | carboplatin cisplatin combination therapy lobaplatin non-small-cell lung cancer |
| ISSN号 | 0959-4973 |
| DOI | 10.1097/CAD.0b013e328352cc10 |
| 文献子类 | Article |
| 英文摘要 | Objective Lobaplatin is used to treat patients with breast cancer, small-cell lung cancer, and chronic myelogenous leukemia in China. In this study, we assessed the in-vitro and in-vivo activities of lobaplatin alone or in combination with antitubulin agents against human non-small-cell lung cancer (NSCLC). Methods The cytotoxicities of lobaplatin against NSCLC cells were determined by the sulforhodamine B (SRB) assay. Cell cycle analysis and apoptosis were assessed using flow cytometry, and the in-vivo antitumor activities were evaluated in human NSCLC xenografts in nude mice. Results The cytotoxicity of lobaplatin was similar to or higher than that of cisplatin and carboplatin, with a mean IC50 of 2.5 mu mol/l in a variety of NSCLC cells. In addition, lobaplatin arrested cells in the S phase and triggered apoptosis. The combination of lobaplatin with antitubulin agents yielded synergistic cytotoxic activity in vitro. In NSCLC xenografts, lobaplatin alone showed significant antitumor activity. The combination of lobaplatin with antitubulin agents, especially with paclitaxel, led to significantly enhanced activity, which was superior to that of cisplatin combined with antitubulin agents. Conclusion These data demonstrate that the use of lobaplatin alone or in combination with antitubulin agents might be a rational and novel therapeutic strategy for human NSCLC and warrants further clinical investigation. Anti-Cancer Drugs 23:698-705 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. |
| WOS关键词 | PHASE-I ; 1ST-LINE TREATMENT ; CISPLATIN ; CARBOPLATIN ; D-19466 ; LINES ; PHARMACOKINETICS ; CHEMOTHERAPY ; PATIENT ; OVARIAN |
| 资助项目 | National Natural Science Foundation of China[30801404] |
| WOS研究方向 | Oncology ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000305894700004 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/278006]  |
| 专题 | 药理学第一研究室 |
| 通讯作者 | Lou, Li-Guang |
| 作者单位 | Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xie, Cheng-Ying,Xu, Yong-Ping,Jin, Wei,et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer[J]. ANTI-CANCER DRUGS,2012,23(7):698-705. |
| APA | Xie, Cheng-Ying,Xu, Yong-Ping,Jin, Wei,&Lou, Li-Guang.(2012).Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.ANTI-CANCER DRUGS,23(7),698-705. |
| MLA | Xie, Cheng-Ying,et al."Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer".ANTI-CANCER DRUGS 23.7(2012):698-705. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。